Daniel Borja-Cacho

Plain English
This study reviewed the use of Yttrium-90 radioembolization to treat intrahepatic cholangiocarcinoma (iCCA), a serious liver cancer with few treatment options. It found that patients receiving a personalized treatment plan using this method lived an average of 14.9 months, compared to 5.5 months with standard approaches. Combining this treatment with other therapies can extend survival to about 32.5 months, making it a promising option for certain patients, especially those with smaller tumors and good liver function.

Plain English
The study compared two methods of liver surgery for living donors: fully robotic and traditional open surgery. Researchers found that the robotic method resulted in much less blood loss, with an average of 77 mL compared to 316 mL in open surgery, and had lower complication rates (6% for robotic vs. 18% for open). This matters because using robotic surgery helps ensure safer experiences for donors and can improve outcomes for patients who receive the liver.

Plain English
This study looked at how a specific procedure called the modified Hutson loop access (MHLA) is used to treat complications in liver transplant patients, focusing on issues like bile duct blockages and leaks. Out of 201 procedures performed on 52 patients, the success rate was very high at 95%, with only 2% of procedures failing when using an endoscope, compared to 13% without it. These findings are important because they show that using the MHLA with endoscopy is a safe and effective way to manage post-transplant complications, which can lead to better patient outcomes and fewer additional procedures.

Plain English
This study looked at how well organs from "non-ideal" donors—like older or less healthy people—could be used for transplants in the U.S. Over 15 years, they found that nearly 25% of the 132,465 donors studied were considered non-ideal. The use of organs from these donors is increasing, particularly for livers, hearts, and lungs, which is important because it could help more patients receive the life-saving transplants they need.

Plain English
Livers stored on ice before transplant suffer ischemia damage that worsens outcomes. This randomized trial tested a portable device that keeps the liver oxygenated and perfused during transport, compared to standard cold storage. The results support that hypothermic oxygenated machine perfusion reduces injury and could become a new standard for liver preservation in the U.S.

Plain English
Researchers studied the personality traits of 263 patients with cirrhosis who were being evaluated for liver transplants. They found that these patients were generally more open, extroverted, agreeable, and neurotic than the average person, but less conscientious. Importantly, those with higher conscientiousness were nearly three times more likely to receive a liver transplant, highlighting that personality can significantly affect treatment outcomes in liver disease.

Plain English
This study looked at the health of organ donors in the U.S. from 2005 to 2019 to see how it affects the number of organs available for transplants. It found that while donors are getting younger and have higher rates of obesity, diabetes, and other health issues, more of them are still being used for transplants—93.9% of potential donors were used. This matters because it highlights that even donors with serious health problems are being considered, which could help address the ongoing shortage of organs for people needing transplants.

Plain English
Researchers studied a method called Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) to improve liver transplantation chances for patients with cirrhosis who have a blocked portal vein. They found that this technique effectively restores normal blood flow in the liver, allowing for better surgery outcomes. This matters because it makes more cirrhotic patients eligible for liver transplants, potentially saving many lives.

Plain English
This study looked at the process of evaluating living donors for liver transplants. Researchers found that careful screening of potential donors is crucial to ensure both their safety and the success of the transplant. This is important because it helps increase the number of available livers for transplant, which can save lives in patients with severe liver disease.

Plain English
Researchers studied two noninvasive tests, CAP and LSM, to assess liver conditions in deceased donors for transplantation. They found that CAP can accurately identify moderate-to-severe fat in the liver, with a 100% accuracy rate for ruling out significant fat at a certain level, while LSM effectively detects liver scarring and identifies unsuitable organs. This is important because using these tests could improve the selection of liver donors, potentially leading to better transplant outcomes.

Plain English
This study looked at liver transplants from donors who had died from circulatory failure, focusing on the best possible outcomes to establish global benchmarks. They analyzed over 2,200 cases and found that in the best situations, just 4.5% of patients needed a new transplant within a year, while 8.4% died, but more than half faced serious complications. These benchmarks help evaluate new techniques and compare different transplant methods, emphasizing that while survival rates are good, many patients still experience significant health issues after surgery.

Plain English
This study focused on improving the selection process for liver transplants using a tool that assesses the quality of donor livers. Researchers examined data from nearly 17,000 liver transplants and created two scoring systems, the LTAB and Mini-LTAB, to categorize the risk of graft failure based on factors like donor age and liver condition. Using these scores helps doctors better predict the chances of success for liver transplants, so they can make more informed decisions about using donor livers that may not be in perfect condition.

Plain English
This study looked at two groups of patients with serious portal vein blockages who needed liver transplants: one group had a procedure called PVR-TIPS to help clear the blockage, while the other group did not. Out of 49 patients analyzed, those who had PVR-TIPS showed significant improvement in blood flow, but both groups had similar survival rates after their transplants. This matters because it shows that PVR-TIPS can effectively ease surgery for patients with tough vein blockages, making liver transplants safer and more straightforward.

Plain English
This study looked at how using a test called the Coronary Calcium Score (CAC) can help assess heart disease risk in patients with serious liver disease who are being evaluated for liver transplants. Out of 148 patients, about 28% had high CAC scores, which indicated a greater risk for serious heart issues. The findings show that if patients have a CAC score below 100, they can safely go ahead with a liver transplant without additional heart tests, while a score below 346 can reliably rule out severe heart disease, making the CAC test an important tool for these evaluations.

Plain English
This study looked at liver transplants from donors who died from cardiac issues, examining their outcomes from 2006 to 2016 at a major hospital. Out of 96 patients, 91% survived their first year after the transplant, but about 30% had biliary problems within that year, with nearly 18% experiencing a specific serious condition called ischemic cholangiopathy. Although survival rates have improved for these transplants over time, the prevalence of biliary complications is significant, highlighting the need for better monitoring and early treatment for affected patients.

Plain English
This study examined the long-term outcomes of liver transplants in 207 patients with liver cancer who initially received a treatment called Yttrium-90 radioembolization to shrink or control their tumors. The findings revealed that, on average, patients lived about 12.5 years after their transplant, with survival rates of 84% at three years and 60% at ten years. Importantly, those whose tumors showed extensive or complete damage after treatment had better chances of not having their cancer return, highlighting the benefit of using Y90 as a pre-surgery treatment.

Plain English
Researchers studied the safety and effectiveness of a treatment called segmental yttrium-90 radioembolization for patients with liver cancer after a procedure that helps with blood flow in the liver. They found that this treatment had a 0% death rate within 30 days, and it successfully reduced tumors in 58% to 74% of patients, depending on the evaluation criteria. Importantly, 88% of patients eligible for a liver transplant received one within about six months, showing that this treatment can effectively help patients waiting for surgery while keeping them stable.

Plain English
This study examined a technique for treating liver tumors that are difficult to reach with standard methods. In a group of 15 patients with various types of liver cancer, doctors used a special balloon catheter to better direct radiation treatment. Out of the cases treated, 11 patients had their tumors completely disappear and 6 had significant shrinkage, making this a promising option for patients with hard-to-reach tumors.

Plain English
Researchers studied a new way to treat a severe complication called hepatic artery thrombosis (HAT) that can happen after a liver transplant, which affects about 5% of patients. They found that using a special device called a stent retriever can effectively restore blood flow in these patients, offering a less invasive alternative to the traditional surgery usually needed. This is important because HAT can lead to serious health issues and even death if not treated quickly, so finding effective treatments like this can save lives.

Plain English
Researchers studied a 22-year-old woman who had severe left flank pain and blood in her urine for four years. After various tests, they discovered she had a condition called posterior nutcracker syndrome, where a vein was compressed, causing her symptoms. The patient had surgery to remove the affected kidney and then successfully had it transplanted to the other side of her abdomen; she is now symptom-free. This matters because it shows that this rare syndrome can lead to significant symptoms and that surgical intervention can effectively resolve them.

Plain English
Researchers studied a new cancer drug called MT477 to see how well it slows tumor growth in a specific type of cancer. They found that when mice with tumors were given MT477 continuously at a dose of 1 mg/kg, the size of their tumors was about 62% smaller compared to those not receiving the drug, and the treatment caused little to no harm to the mice. This matters because it shows that MT477 could be an effective treatment option with low toxicity for certain cancers that do not have mutations in a gene called Ras.

Plain English
This study looked at using a drug called bortezomib during the early phase of kidney transplants to help patients with difficult antibody issues. A specific transplant case showed that after using bortezomib, the patient had good kidney function and did not experience immediate rejection, although they later died from unrelated complications. This is significant because it demonstrates that bortezomib can be safely used in the transplant process, potentially improving outcomes for challenging cases.

Plain English
The study looked at a new compound called MT477 and its effects on tumor cells in laboratory tests and mice. Researchers found that MT477 significantly reduced tumor growth by about 49.5% in mice and affected various gene activities related to cancer development. This is important because it shows that MT477 could be a promising new treatment option for certain types of cancer.

Plain English
Researchers studied the effects of the compound myricetin on pancreatic cancer cells and found that it caused the cancer cells to die without harming normal cells. In lab tests, myricetin led to tumor shrinkage and reduced cancer spread in mouse models. This is important because pancreatic cancer is difficult to treat, and myricetin could be a safe new option for therapy.

Plain English
This study looked at a combination of two drugs, TRAIL and triptolide, to see if they could effectively kill pancreatic cancer cells. The researchers found that using both drugs together significantly reduced the survival of cancer cells and led to more cell death compared to using either drug alone. This is important because pancreatic cancer is usually hard to treat, so finding effective combinations like this could improve treatment options for patients.

Plain English
This study examined how triptolide, a natural compound, kills pancreatic cancer cells. It found that triptolide can trigger cell death in two ways: by causing cells to undergo apoptosis (a form of programmed cell death) in some cancer cell lines and autophagy (a process that breaks down and recycles cell components) in others. This is important because it shows that triptolide could be a promising treatment against various types of pancreatic cancer, which currently have few effective options.

Plain English
This study looked at how well the American College of Surgeons National Surgery Quality Improvement Program (ACS NSQIP) predicts serious problems after major cancer surgeries. Researchers analyzed data from over 15,000 patients and found that while only 2.5% died within 30 days of surgery, nearly 24% faced significant complications. The current system was not very good at predicting these complications accurately and might need to include more specific information about the patients' conditions and surgeries to improve future predictions.

Plain English
Researchers studied the effects of a compound called triptolide on neuroblastoma, a type of cancer, and found that it significantly reduced tumor size and caused cancer cell death by lowering levels of a protein called Hsp-70. In experiments, silencing Hsp-70 in cancer cells led to more cell death and increased signs of apoptosis, similar to what happened with triptolide treatment. This is important because it shows that targeting Hsp-70 could enhance treatments for neuroblastoma, potentially improving outcomes for patients.

Plain English
Researchers studied the effects of combining two treatments, triptolide and TRAIL, on cholangiocarcinoma, a type of cancer affecting bile ducts. They found that using these two therapies together killed more cancer cells than either treatment alone, showing a significant decrease in cell survival—almost doubling the cell death rate compared to using just one drug. This combination is important because it may offer a more effective way to treat this challenging cancer by boosting the body's ability to trigger cancer cell death.

Plain English
This study looked at how a protein called HSP70 helps cancer cells survive by preventing cell death (apoptosis). Researchers found that when they reduced HSP70 levels in pancreatic cancer cells, it led to increased calcium levels inside the cells and damaged lysosomes, which activated pathways that caused the cells to die. This matters because understanding how HSP70 protects cancer cells could help in developing treatments for pancreatic cancer and possibly other types of cancer.

Plain English
This study looked at the causes of acute abdominal pain in 73 patients with systemic lupus erythematosus (SLE) who were treated in the emergency room. The most common reasons for their pain were pancreatitis (29%) and intestinal ischemia (16%). It found that a specific risk score, the APACHE II score, was linked to higher mortality rates, with an overall death rate of 11%, highlighting the need for quick diagnosis and effective treatment to improve patient survival.

Plain English
Researchers studied the effects of a treatment called triptolide on neuroblastoma, a type of cancer, both in lab dishes and in mice. They found that triptolide made cancer cells die more effectively and reduced tumor size in mice, with tumors being significantly smaller in treated mice compared to those that didn't receive the treatment. This matters because it shows triptolide could be a promising new way to fight neuroblastoma.

Plain English
Researchers studied new drugs that target specific mutations in pancreatic cancer cells, which often resist standard treatments. They found that combining traditional therapies with these targeted drugs shows promise, but most of the current evidence comes from small safety trials. This is important because better targeting of pancreatic cancer could lead to more effective treatments, improving outcomes for patients with this aggressive disease.

Plain English
Researchers studied how triptolide, a natural compound, affects pancreatic cancer cells. They found that triptolide kills these cancer cells by reducing a protein called HSP70, which helps cancer cells survive; in lab tests, it decreased cell viability by up to 80% and significantly slowed tumor growth in mice. This matters because pancreatic cancer is tough to treat, and triptolide could become a promising new treatment option to help control this disease.

Plain English
This study looked at a patient who had surgery to fix a bile duct injury and later experienced problems due to a rare cause—a parasitic worm infestation. The patient suffered from symptoms like intermittent infections and high levels of certain white blood cells, and during surgery, doctors discovered that the worm was blocking the connection made during the repair. This highlights the importance of considering unusual infections when patients have complications after bile duct surgeries.

Plain English
Researchers studied a new surgical method to repair thin bile ducts that can be damaged during medical procedures. They found that this technique, called laterolateral hepatojejunostomy, successfully connects the damaged bile ducts to the intestines, providing a wider opening for bile flow. This matters because it improves the chances of recovery for patients with complicated bile duct injuries, making their treatment safer and more effective.